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ABSTRACT 
 
IGF2 is an imprinted gene found on chromosome 11. Epigenetic gene 
deregulation is increasingly shown to play a role in many types of cancer. Imprinted 
genes are especially susceptible to epigenetic regulatory changes because of silencing of 
one allele and the dependence on proper methylation for normal function. One of the 
goals in cancer research is to identify molecular markers that will predict the onset of 
specific cancers. The pattern of methylation across the IGF2 gene can be used to 
characterize the difference between normal and cancerous tissue, as well as the difference 
between different tumor tissues. By developing methylation assays that can determine the 
levels of methylation for all of the CpG sites across genes, we can establish patterns that 
could be predictive in detecting the onset of specific cancer types. We have developed 
assays to test the methylation levels at several sites across the IGF2 gene, and have 
assayed those levels in DNA isolated from breast, cervical, ovarian, and colon cancers 
and compared it to the corresponding normal tissue DNAs.  The data shows that there are 
unique patterns of methylation between normal and cancerous tissues, and distinct 
methylation patterns across different types of cancers. The differences in methylation 
patterns between DNA isolated from tumor and normal adjacent tissue across four 
different tumor types in these genes indicates the critical influence of epigenetic 
regulation in this IFG2 region on the progression of cancer. 
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BACKGROUND 
 
Cancer 
 Cancer, put quite simply, is the uncontrolled growth of cells within the body.   
Known medically as malignant neoplasm, cancer comes in many forms, and can arise 
from many different types of tissues within the body.  Through the process of 
oncogenesis, certain genes in a cell become altered, and the genes that regulate cell 
growth and division no longer operate correctly (Figure-1).  Because the tumorigenic 
cells arise from normal cells in the body, cancer can be very difficult to detect in the early 
stages.  The origin of the cancerous cells also makes treating the disease difficult because 
an agent that could damage the cancer cells could also cause harm to normal cells.  The 
likelihood for the onset of oncogenesis may be influenced by many external and internal 
factors such as tobacco use, chemicals, radiation, inherited mutations, or hormones 
(National Cancer Institute, 2012).  All of these forces may act together, or in sequence, to 
alter the genes that regulate growth and division.  
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Figure 1: Diagram of Cancer Pathology.  Normal cell division 
is shown in the upper panel, and cancer cell division in the lower 
panel.  Note that a leading theory about cancer formation is the 
accumulation of mutations to the genes controlling cell growth 
and division that leads to tumors that can spread throughout the 
body.  (National Cancer Institute, 2012) 
 
 The genes that promote growth, are called oncogenes when their expression can 
cause cancer.  These powerful growth genes become overexpressed in cancer, while 
tumor suppressor genes meant to act as checkpoints in cell division become silenced.  
The cells then grow and divide rapidly, forming malignant tumors that can invade other 
parts of the body via the blood stream and lymphatic system to other organs disrupting 
necessary bodily functions.  The mortality of the disease varies greatly depending on the 
type and location of the tumors as well as how much it has spread.  Treatment is usually 
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in the form of surgery, radiation therapy, and/or chemotherapy, all of which take a heavy 
toll on the patient.  The diagnosis of cancer is often only made after the tumors are large 
enough to cause symptoms, but regular screenings have increased the chances of catching 
it in the earlier stages, so the prevalence of some types of cancers has fallen in the last 
few years.  Early detection greatly increases the chance of successful treatment.  It is 
estimated that nearly 12 million Americans today have been affected by cancer, with an 
expected 1.64 million new cases to be added this year (Figure-2) (Cancer Facts, 2012).  
Cancer is the number two killer of Americans, at a rate of more than 1,500 deaths a day 
(Cancer Facts, 2012). 
 
 
 
Figure 2: Leading Causes of Cancer and 2012 Estimates.  
Shown are the estimated incidence for new cases for various 
types of cancer in 2012, and the estimated deaths from various 
types of cancer (Cancer Facts, 2012). 
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The incidence of cancer has increased steadily over the years due to longer life 
spans and other environmental factors.  In 2008, cancer is credited for 13% of all deaths 
worldwide with 7.6 million cases.  This number is expected to swell to 13.1 million by 
2030 (World Health Organization, 2012).   The data in Figure-3 shows that nearly one 
half of men alive today, and one third of women, are likely to be affected by cancer in 
their lifetime.  As a disease that affects such a large percent of the population, a reliable 
system for detection and treatment would undoubtedly save many lives and raise the 
quality of life for billions.   
 
  
Figure 3: Cancer Probabilities.  Shown are the likelihood for men (left panel) 
and women (right panel) for developing various types of cancer over a lifetime 
(Cancer Facts, 2012). 
 
 
Screening programs have been encouraged in many countries, and have resulted 
in increased early detection and a lower mortality rate.  A major issue that still exists is 
that cancerous tissue is difficult to distinguish from normal tissue, especially in the early 
stages.  An accurate and diagnostic epigenetic assay would greatly aid such efforts by not 
only providing a clinical diagnostic tool but also by assessing the risk that tissues will 
become cancerous in the future.   
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Epigenetics 
 Although most people today are familiar with the basis of DNA and genetics, 
epigenetics has been of rising prominence and attention.  Epigenetics is considered the 
study of changes in gene expression in the absence of modification of the underlying 
DNA sequence.  The operation of the epigenome is very complex and not fully 
understood, but it seems that it is partially inherited from the parents, but unlike the 
genome, it is also subject to change from environmental pressure.  Environmental factors 
such as diet and stress can often affect the expression of certain genes, and since the 
sequence in the DNA does not change, except in the case of mutagenesis, there must be 
some other venue for control (Eccleston et al., 2007).  A good analogy is that the genome 
is like the computer hardware, static and unchanging, while the epigenome is the 
software, directing gene expression in response to environmental influences.   
Some of the epigenetic pathways that affect gene expression are histone 
modification and DNA methylation.  DNA methylation occurs when a methyl group 
attaches to the cytosine base of the DNA double helix, frequently at CG sites (Figure-4).  
Such areas, known as CpG sites, tend to occur in patterns all along the genome, often 
clumping around genes in areas known as CpG islands.  It is believed that when these 
areas become methylated, the methyl group changes the DNA’s affinity for certain 
transcription factors (Jones, 1980; Phillip, 2008).   
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Figure 4: Diagram of DNA Methylation at CpG Islands.  DNA methylation 
occurs when a methyl group composed of a carbon atom and three hydrogen 
atoms binds onto the cytosine in the DNA double helix. This can cause changes 
in the expression of the gene including silencing by preventing the binding of 
regulatory factors.  (Max Planck Institute of Psychiatry, 2012) 
 
 
Contrary to previous conceptions, methylation does not automatically mean gene 
expression down regulation, instead the effect of methylation depends upon the default 
state of the region.  DNA methylation has been shown to be important in cell 
differentiation, where it turns certain genes on and off in sequence to guide the cells on 
their way from a pluripotent stem cell into a fully differentiated cell (Jones, 1980).  
Aberrant methylation or de-methylation of CpG sites would be able to cause the 
abnormal expression of the growth regulation genes.  DNA methylation’s ability to 
control gene expression made it a suspect in the oncogenic process, and there have been 
several studies that show a strong correlation between the two (Das, 2004; Momparler 
and Bovenzi, 2000).  As a result, several studies have looked at drugs with the potential 
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to alter the methylation of DNA to affect gene regulation (Szyf, 1996; Issa and 
Kantarjian, 2009).  An assay designed to reliably and accurately assess gene methylation 
status coupled with an effective system for altering the methylation states, could lead to a 
very effective treatment option or in prevention.    
 
Genomic Imprinting 
 Genomic imprinting is a genetic occurrence where a specific gene is expressed in 
a parent-of-origin-specific way.  Unlike Mendelian genomics, only the non-imprinted 
gene from one parent is always expressed, while the other is silenced.  The mechanism of 
this gene silencing is through methylation and histone modification (Figure-5).   
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Figure 5: Mechanism of Genomic Imprinting.  Shown is the means by which 
imprinted methylated genes (orange) are inherited.  Only one version of each 
gene is expressed in a parent of origin-dependent way (Wilkinson et al., 2007).   
 
 
The appropriate suppression of imprinted genes is necessary for normal 
development.  Improper imprinting has been associated with many genetic disorders such 
as the Beckwith–Wiedemann syndrome, Silver–Russell syndrome, Angelman syndrome 
and Prader–Willi syndrome (Reik, 1989; Nicholls, 2000).  Imprinted genes are especially 
susceptible to epigenetic regulatory changes because of silencing of one allele and the 
dependence on proper methylation for normal function.  Either loss of imprinting or 
changes of methylation of the non-imprinted copies could have drastic effects on the 
expression of the gene.  Due to the importance of imprinted genes for normal cell 
development, and their vulnerability to epigenetic changes, make them likely players in 
the oncogenic process.    
 
IGF2 
 IGF2 is a gene located on chromosome 11p15.5 which codes for the insulin-like 
growth factor 2 protein.  IGF2 is a growth and proliferation-promoting gene that is 
essential in growth and development before birth, but becomes less active in adulthood.  
IGF2 is an imprinted gene with only the paternal copy being expressed (Figure-6).  
Because of its involvement in cell proliferation and its vulnerability to epigenetic changes 
due to imprinting, IGF2 is likely to be involved in some forms of oncogenesis.  Several 
studies have been performed in IGF2 and have linked loss of imprinting of the IGF2 gene 
to cancer (Jirtle, 2004; Sakatani, 2005).  For all these reasons, IGF2 was selected as the 
target for the methylation analysis assays in this project.   
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Figure 6:  Imprinting and IGF2.  Shown is an experiment highlighting the 
importance of the proper functioning of the IGF2 in normal growth and 
development.  (University of Utah, 2012) 
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PROJECT PURPOSE 
 
The purpose of this project is to determine the methylation state of the IGF2 gene 
promoter and selected internal regions, for both normal and cancer tissue for various 
tissue types.  The data will then be analyzed to potentially identify differentially 
methylated regions between the sample sets to determine specific methylation profiles for 
the normal and cancerous types. Then the profiles will be assessed to determine the 
viability of using DNA methylation analysis and known methylation profiles as a 
diagnostic test for cancer.  The hope is that this research will be used as a risk assessment 
procedure and early detection diagnostic assay which would greatly reduce the mortality 
of the disease.   
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METHODS 
 
DNA Extraction 
 
 The tissue lines and tumor tissues were acquired from ProteoGenex, Inc.  There 
were 80 samples overall used in this experiment, representing four different tissue types: 
Breast, Colon, Ovarian, and Cervical; half of which were cancerous and half of which 
were normal, amounting to 10 samples for each tissue type and cancer state.  gDNA 
(genomic DNA) was extracted from the tissues using a Zymo Research ZR-96 Quick-
gDNA
TM
 (Zymo Research).  The tissue was first digested in Proteinase K and Genomic 
Lysis buffer.  The samples were then centrifuged, and the supernatants were then added 
to the Silicon-A Plate.  The Silicon-A Plate was then placed on top of a Collection Plate 
and centrifuged.  The aim of this procedure is to collect the DNA in the filter at the 
bottom of the Silicon-A plate while all the other cell parts flow through into the 
collection plate.  After the centrifuging, the flow through was discarded and some DNA 
Pre-Wash Buffer was added to the Silicon-A Plate columns and centrifuged over the 
Collection Plate.  The flow through was discarded and another was carried out in the 
same manner, but this time the g-DNA Wash Buffer was used.  The purpose of the 
repeated washes is to clear out any other cellular debris besides the DNA.  After the third 
wash, DNA Elution Buffer was added to each of the columns of the Silicon-A Plate was 
placed on top of an Elution plate and centrifuged.  The purpose of this step is to remove 
the DNA from the filter at the bottom of the Silicon-A Plate and collect the extracted 
gDNA in the Elution Plate for use in the experiment.  After the centrifuging, the Elution 
Plate containing all the gDNA samples was labeled and stored in a -80°C freezer for later 
use.   
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DNA Bisulfite Treatment 
 
 The extracted gDNA was subject to bisulfite conversion in preparation for PCR 
using the Zymo Research EZ-96 DNA Methylation
TM
 Kit (Zymo Research).  The gDNA 
was removed from the freezer and thawed before being added to a Conversion Plate.  
Then 5 ul of M-Dilution Buffer was added to each sample, and the final volume was 
brought to 50 ul using water.  The samples were then allowed to incubate at 37°C for 15 
minutes in order to denature the DNA.  After the incubation, CT Conversion Reagent was 
added to each sample and mixed.  The Conversion Plate was then put in a thermo cycler 
and allowed to incubate in the dark overnight.  The sodium bisufinate contained in the CT 
Conversion Reagent will convert all the unmethylated cytosines into uracils by way of 
the chemical reaction shown in Figure-7.   
 
 
 
 
Figure 7: Diagram of the DNA Bisulfite Reaction.  In bisulfite 
conversion, sodium bisulfate converts all unmethylated cytosines 
into uracils (Schumacher, 2007). 
 
 
 The fact that only the methylated cytosines are converted into uracils will become 
important in determining the methylation state later on.  After the overnight incubation, 
the bDNA (bisulfite DNA) was incubated at 0- 4°C for 10 minutes.  M-Binding Buffer 
was then added to a Zymo-Spin™ I-96 Binding Plate on top of a Collection Plate.  The 
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bDNA was then added to the spin plate and mixed.  The samples were then centrifuged, 
and the flow through was discarded.  Then the samples were washed and centrifuged 
using M-Wash Buffer, and the flow through was discarded.  M-Desuphonation Buffer 
was then added to each sample and allowed to stand at room temperature.  After the 
incubation, the plate was again centrifuged and the flow through discarded.  Two more 
rounds of washing with M-Wash buffer followed to remove any unwanted material.  The 
Zymo-Spin™ I-96 Binding Plate was then placed on top of An Elution Plate.  M-Elution 
Buffer was then added and the bisulfite converted DNA was collected on the Elution 
Plate.  The plate was then labeled and stored in a -80°C freezer for later use.   
 
 
Assay Design 
 
 
 The next two procedures, PCR and pyrosequencing rely on DNA replication 
technology.  In order for either of these procedures to work, sequence-specific primers 
must be designed to ensure the sequence of interest is being replicated.  The primers used 
are short sequences, about 20 bp long, that are complimentary to sequences flanking 
either side of the area of interest.  The regions selected were varied, some were regions 
known to be differentially methylated while others were promoters or CpG islands.  
There are several factors that can affect the operation of the primer, so the assays were 
developed using Qiagen’s PyroMark Assay Design Software 2.0.  The exact sequences 
used for the primers and the procedure for deriving them are proprietary property of 
EpigenDx, Inc. and will not be discussed here.  Once the assay had been designed, the 
primers were ordered from Biomers.net, an oligonucleotide manufacturing service.  The 
areas of the IGF2 gene covered by the assays in this experiment are shown in Figure-8.   
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Figure 8: The Location of the IGF2 Methylation Assays.  Exons are shown as 
white boxes, and promoters are labeled as P (P0, P1, P2, etc.).  CpG islands are 
labeled with bars and the assays designed to the specific regions are shown.  Red 
balloons indicate CpG sites covered by EpigenDx assays, while the green 
balloons show CpG sites not yet covered by EpigenDx assays 
 
 
PCR 
 
 PCR (Polymerase Chain Reaction) is a widely used method of DNA 
amplification. It works by using the primers and DNA polymerase to build new segments 
of DNA off the original copies (Figure-9).  The plate containing the bDNA was thawed 
along with all the reagents needed.  The reagents were then added to the samples, 
including the primers, DNA polymerase, individual nucleotides and some buffer.  The 
plate was then put into a thermocycler which heats and cools the samples to a specific set 
of temperatures in repeated cycles.  There are three steps to the thermo cycling process, 
and they are repeated about 40 times, each time making more copies of the DNA.  In the 
ADS3062 
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first step, the samples were heated to about 94°C, this is known as the denaturation step 
during which the DNA unravels and splits off into two single stranded copies.  Next is 
the annealing step, where the samples were brought to about 54°C and the primers that 
were added bind to the complementary sequence of DNA.  The last step is extension, 
where the samples were heated again to about 72°C, at which time the DNA polymerase 
binds to the DNA and uses the free nucleotides to build a complimentary strand.  Because 
these steps are repeated, there are more templates to build off of each cycle and the 
number of copies of the DNA exponentially increases.  Also of note is that the new 
copies of DNA will have thymine in place of the uracils that were inserted during the 
bisulfite conversion.  Using this method allowed the DNA concentration to be increased 
to a point sufficient for pyrosequencing.  Once thermocycling was completed, the 
samples were kept at 4°C in the thermocycler until pyrosequencing.   
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Figure 9:  Diagram of the Polymerase Chain Reaction.  Through repeated 
heating and cooling the DNA segments are able to be replicated many times, and 
amplified.  (Orac, 2007) 
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Pyrosequencing 
 
 Pyrosequenceing is a method of DNA sequencing that uses a cascade of enzyme 
activities to read short sequences of DNA.  The idea of it is similar to that of PCR, except 
that instead of just copying the sequence using DNA polymerase, the activity of DNA 
polymerase is measured as it adds each individual nucleotide to the sequence. The first 
step was to aliquot out some streptavidin sepharose beads into a pyrosequencing plate.  
The DNA binds to these beads very strongly keeping them still while also orienting the 
strands uniformly.  The samples are added to the bead solutions and put on a horizontal 
shaker to ensure the DNA binds to beads.  Once the samples were sufficiently shaken, the 
beads, along with the DNA attached to them were sucked out of the plate using a 
PyroMark® Q96 Vacuum Workstation.  This consists of a vacuum handle with 96 probes 
that come down into the wells of the plate.  The probes have holes in them but they are 
just small enough not to let the beads pass through.  Suction is kept on to the beads and 
DNA is stuck as they are subjected to various washes.  The first wash is an ethanol bath, 
which removes any unwanted residues.  The next bath was in a Denaturation Solution, 
which stripped one copy of the DNA off, leaving only single stranded DNA attached to 
the beads.  The beads were then subjected to a wash buffer to remove any remaining 
ethanol or Denaturation Solution that would affect the pyrosequencing reaction.  A 
pyrosequencing plate was then filled with the sequencing primer complimentary to the 
area immediately upstream from the target sequence.  After the final wash, the beads and 
DNA were added to the pyrosequencing plate and heated to 80°C to ensure proper 
annealing.  The plate was then loaded into a Qiagen PyroMark Q96 MD for analysis.   
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Pyrosequencing functions by reading the activity of DNA polymerase as it adds 
nucleotides to the DNA strand (Figure-10).  Once the primer and polymerase have bound 
the sequence in question, the pyrosequencing machine adds more enzymes, then proceeds 
to sequentially flood each well with one of the the four dNTPs (deoxynucleoside 
triphosphates) one at a time.  If the dNTP just added happens to be complimentary to the 
next base in the DNA sequence, the polymerase will add it.  When this happens, the 
polymerase releases a pyrophosphate, which is taken up by ATP sulfurylase and 
converted to ATP.  The ATP is then taken up by luciferase which uses it to convert 
luciferin to oxyluciferin.  This process gives off a visible light which can be read by 
photoreceptors in the pyrosequencer.  Unincorporated dNTPs are degraded by the 
addition of an apyrase enzyme so that they are no longer present during the addition of 
the next dNTP.  By measuring the light given off after the addition of each nucleotide, the 
sequence of the DNA strand can be read.  The light given off is proportional to the 
number of nucleotides added so if the peak is twice as high, it means two nucleotides 
were added.   
 
 
Figure 10: Diagram of Pyrosequencing.  This figure diagrams the chemical 
pathway used by the pyrosequencer to read the sequence.  The graph top the left 
is atypical readout with the nucleotide added and the sequence of the DNA at the 
top (Nature Methods, 2005). 
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 Because all the unmethylated cytosines were converted to uracils during the 
bisulfite treatment then to cytosines in the PCR reaction, the only cytosines that remain 
were the ones that were methylated.  By comparing the signals given off during the 
addition of thymidine and cytosine at a CpG site, the percent methylation of the original 
site can be deduced (Figure-11).   
 
 
Figure 11: Example Result from a CpG Site.  The percent methylation 
is directly correlated to the ratio of the signals given off during the 
addition of thiamine and cytosine.  (EpigenDx, 2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T     C 
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RESULTS 
 
  
The purpose of this project was to determine the methylation state of the IGF2 
gene at multiple locations, for both normal and cancer tissue of various tissue types.  The 
data was then be analyzed to identify differentially methylated regions between the 
sample sets to determine specific methylation profiles for the various normal and 
cancerous tissue types. This was accomplished through DNA methylation analysis by 
pyrosequencing.   
The results are very promising, revealing several differentially methylated regions 
across all the sample sets (Figure-12).  The cancer tissues seem to be hypomethylated 
overall, but this is not the case in all regions.  ADS 1051 (upper right panel) and ADS006 
(lower right panel) both showed hypomethylation of the cancer tissues for all the tissue 
types compared to the normal, while ADS173 (middle left) and ADS172 (middle right) 
showed quite the opposite in all tissue types except for ovarian.  ADS134 (lower left) 
showed variation between the tissue types, but there was no variation in this region 
between the normal and cancerous tissue types.  ADS 3602 (upper left) showed 
hypomethylation of the cancer tissues except for breast, which showed relativity little 
change.   
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Figure 12: Comparative Results for Cancer and Normal Tissue for all the 
Cancer Types.  The assay ID is located above each result, with the percent 
methylation on the left. 
 
 
Although this data may seem rather conflicting, it lends itself to the idea that 
regulation is not a simple matter of hypo- or hyper-methylation, but rather that location 
has an effect on the gene regulation.  A more complete picture can be gained by plotting 
the methylation of each location relative to its actual position on the gene (Figure-13).   
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This methylation map or “methylation profile” is unique to each tissue type, both 
cancerous and normal.   
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Figure 13: Methylation Profiles for All the Tissue Types.  The 
vertical axis represents the methylation at that specific site, while 
the horizontal axis denotes the relative position of the CpG site.   
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DISCUSSION 
 
In this project, an analysis of the methylation levels of different regions of the 
human IGF2 gene was performed for four tumor types (breast, colon, ovarian and 
cervical) and their corresponding normal tissue.  Several locations within the IGF2 gene 
were analyzed including the promoter of the P0 exon, the DMR0 region, the CpG island 
(CpG 3) proximal to the P3 exon, and the CpG island (CpG 4) in the last exon.  Within 
the promoter region of the P0 exon, each tumor type showed a unique pattern of 
methylation. All tumors were slightly hypomethylated as expected for an over-expressing 
growth related gene, but the breast tumor least of all. In one region of the promoter there 
was a large hypomethylation of tumor tissue in ovarian tumors where a more proximal 
assay showed greater hypomethylation in the cervical tumors. There was significant 
hypomethylation in all tissue types within the DMR0 region, with ovarian tumors 
showing the largest difference to normal tissue. The methylation patterns observed in the 
CpG 3 island show distinct differences within this region. These assays show low levels 
of methylation in the normal tissues. Assay ADS 134 in the proximal region shows no 
difference between normal and tumor tissue in any of the different tumor types as seen in 
the ADS 134 bar graph and its corresponding region on the line graph. However, each of 
the more distal CpG 3 assays show unique patterns of hypermethylation in tumor tissue. 
The CpG 4 island assay consistently showed modest hypomethylation in all tumors when 
compared to their normal counter-parts. 
The differences in methylation patterns between DNA isolated from tumor and 
normal adjacent tissue for 4 different tumor types in the IGF2 genes suggests a critical 
influence of epigenetic regulation in this region on the progression of cancer. The 
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methylation changes in the promoter regions could be potential biomarkers for detecting 
breast cancer, cervical cancer, colon cancer, and ovarian cancer.  It appears that 
methylation analysis as a form of cancer diagnosis is very promising, and further 
investigation is needed. 
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